The Impact of Omalizumab in Allergic Disease – A Review of Therapeutic Benefits

Immunoglobulin E (IgE) plays a central role in the pathogenesis of allergic diseases, including asthma, rhinitis, food allergy, and anaphylaxis. The discovery of IgE led to the development of omalizumab, a recombinant humanized monoclonal antibody that selectively binds circulating IgE, thereby preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils. This reduces the release of inflammatory mediators, downregulates FcεRI expression, and attenuates allergic inflammation. Omalizumab has demonstrated proven efficacy as an add-on therapy for moderate-to-severe allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps, improving symptom control, reducing exacerbations, and enhancing quality of life. Emerging applications include IgE-mediated food allergy, atopic dermatitis, and other allergic or autoimmune conditions. While generally well-tolerated, rare adverse effects such as anaphylaxis and potential cardiovascular events require monitoring. Despite its cost, omalizumab’s clinical benefits and reduction in healthcare utilization underscore its importance as a targeted biologic in IgE-driven diseases.